Table 2.
This table summarizes the seminal trials of the three FDA-approved cyclin-dependent kinase inhibitors for HR+/HER2− breast cancer.
| Trial | N | Regimens | Median OS | Hazard Ratio (95% CI) | p-Value |
|---|---|---|---|---|---|
| PALOMA-3 | 521 | Placebo + fulvestrant | 28.0 months | 0.81 (0.64–1.03) | 0.09 |
| Palbociclib + fulvestrant | 34.9 months | ||||
| MONALEESA-3 | 726 | Placebo + fulvestrant | 51.8 months | 0.72 (0.57–0.92) | 0.004 |
| Ribociclib + fulvestrant | 67.6 months | ||||
| MONALEESA-7 | 672 | Placebo + tamoxifen or NSAI | 48.0 months | 0.71 (0.53–0.95) | 0.009 |
| Ribociclib + tamoxifen or NSAI | 58.7 months | ||||
| MONARCH-2 | 669 | Placebo + fulvestrant | 37.3 months | 0.76 (0.61–0.95) | 0.01 |
| Abemaciclib + fulvestrant | 46.7 months |